JP2023501590A - Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する造血細胞悪性腫瘍のための療法 - Google Patents

Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する造血細胞悪性腫瘍のための療法 Download PDF

Info

Publication number
JP2023501590A
JP2023501590A JP2022527744A JP2022527744A JP2023501590A JP 2023501590 A JP2023501590 A JP 2023501590A JP 2022527744 A JP2022527744 A JP 2022527744A JP 2022527744 A JP2022527744 A JP 2022527744A JP 2023501590 A JP2023501590 A JP 2023501590A
Authority
JP
Japan
Prior art keywords
cells
car
cell
human patient
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022527744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501590A5 (enExample
Inventor
アレクサンダー テレット ジョナサン
デケアン マリー－リー
ビル マティーアス
Original Assignee
クリスパー セラピューティクス アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クリスパー セラピューティクス アクチェンゲゼルシャフト filed Critical クリスパー セラピューティクス アクチェンゲゼルシャフト
Publication of JP2023501590A publication Critical patent/JP2023501590A/ja
Publication of JP2023501590A5 publication Critical patent/JP2023501590A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2022527744A 2019-11-13 2020-11-13 Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する造血細胞悪性腫瘍のための療法 Pending JP2023501590A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962934945P 2019-11-13 2019-11-13
US62/934,945 2019-11-13
US202063034510P 2020-06-04 2020-06-04
US63/034,510 2020-06-04
PCT/IB2020/060718 WO2021095009A1 (en) 2019-11-13 2020-11-13 Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70

Publications (2)

Publication Number Publication Date
JP2023501590A true JP2023501590A (ja) 2023-01-18
JP2023501590A5 JP2023501590A5 (enExample) 2023-11-06

Family

ID=73554470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022527744A Pending JP2023501590A (ja) 2019-11-13 2020-11-13 Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する造血細胞悪性腫瘍のための療法

Country Status (11)

Country Link
US (1) US20220387571A1 (enExample)
EP (1) EP4058051A1 (enExample)
JP (1) JP2023501590A (enExample)
KR (1) KR20220100912A (enExample)
CN (1) CN114845730A (enExample)
AU (1) AU2020384951A1 (enExample)
BR (1) BR112022009290A2 (enExample)
CA (1) CA3158090A1 (enExample)
IL (1) IL292467A (enExample)
MX (1) MX2022005815A (enExample)
WO (1) WO2021095009A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
MX2022015586A (es) 2020-06-12 2023-03-15 Nkarta Inc Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70.
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20220387488A1 (en) * 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
US20230128917A1 (en) * 2021-09-14 2023-04-27 Crispr Therapeutics Ag Genetically engineered immune cells having a disrupted cd83 gene
CN117173092B (zh) * 2023-06-28 2024-04-09 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种基于图像处理的鼻咽癌放疗方法及系统
WO2025193386A1 (en) 2024-03-13 2025-09-18 Caribou Biosciences, Inc. Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019097305A2 (en) * 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
JP2019520076A (ja) * 2016-07-06 2019-07-18 セレクティスＣｅｌｌｅｃｔｉｓ 初代免疫細胞における逐次遺伝子編集
WO2019152742A1 (en) * 2018-02-01 2019-08-08 Pfizer Inc. Chimeric antigen receptors targeting cd70
WO2019215500A1 (en) * 2018-05-11 2019-11-14 Crispr Therapeutics Ag Methods and compositions for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019520076A (ja) * 2016-07-06 2019-07-18 セレクティスＣｅｌｌｅｃｔｉｓ 初代免疫細胞における逐次遺伝子編集
WO2019097305A2 (en) * 2017-05-12 2019-05-23 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
WO2019152742A1 (en) * 2018-02-01 2019-08-08 Pfizer Inc. Chimeric antigen receptors targeting cd70
WO2019215500A1 (en) * 2018-05-11 2019-11-14 Crispr Therapeutics Ag Methods and compositions for treating cancer

Also Published As

Publication number Publication date
MX2022005815A (es) 2022-08-10
CA3158090A1 (en) 2021-05-20
BR112022009290A2 (pt) 2022-08-09
KR20220100912A (ko) 2022-07-18
EP4058051A1 (en) 2022-09-21
US20220387571A1 (en) 2022-12-08
IL292467A (en) 2022-06-01
WO2021095009A1 (en) 2021-05-20
CN114845730A (zh) 2022-08-02
AU2020384951A1 (en) 2022-05-19
AU2020384951A9 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US11389481B2 (en) Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
JP2023501602A (ja) Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用する腎細胞癌（ｒｃｃ）療法
US20220387571A1 (en) Therapy for hematopoietic cell malignancies using genetically engineered t cells targeting cd70
JP2023501611A (ja) Ｃｄ７０を標的化する遺伝子操作されたｔ細胞を使用するｃｄ７０＋固形腫瘍療法
KR20230110737A (ko) Cd19를 표적화하는 유전자 조작된 t 세포를 사용한 b 세포 악성종양의 동종 세포 요법
WO2021260657A1 (en) Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
US20230220059A1 (en) Genetically engineered t cells expressing bcma-specific chimeric antigen receptors and uses thereof in cancer therapy
CN116685337A (zh) 使用靶向cd19的基因工程化t细胞的b细胞恶性肿瘤的同种异体细胞疗法
HK40068210A (en) Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408